Get started
Author

Raymond Despax

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
1996 · G J Creemers, G Bolis, et al. · Journal of Clinical Oncology · 377
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 171
PDF
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 116
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
1986 · G Mathé, Y Kidani, et al. · PubMed · 91
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
Experience with independent radiological review during a topotecan trial in ovarian cancer
1997 · S. Gwythen, G. Bolis, et al. · Annals of Oncology · 28
PDF
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
2020 · Yves Rinaldi, Anne-Laure Pointet, et al. · European Journal of Cancer · 21
Phase II trial of D-Trp-6-LH-RH in advanced breast cancer
1986 · G. Mathé, R. Kelling, et al. · European Journal of Cancer and Clinical Oncology · 19
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
2020 · Anne-Claire Hardy-Bessard, Fabien Brocard, et al. · The Breast · 11
Attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien : résultats de la cohorte française GINECO de l’enquête européenne NOGGO/ENGOT-ov22 (Expression IV)
2018 · Marianne Lorcet, Alain Lortholary, et al. · Bulletin du Cancer · 5
Choriocarcinoma and endocrine paraneoplastic syndromes.
1993 · P Caron, A M Salandini, et al. · PubMed · 3
Abstract P3-12-07: Pharmacogenetic determinants of aromatase inhibitors pharmacokinetics and side effects: 6-month results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295)
2018 · F Thomas, P Marquet, et al. · Cancer Research · 1
Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
2016 · A.-C. Hardy-Bessard, F. Brocard, et al. · Annals of Oncology · 1
PDF
[Anemia in renal insufficiency. Demonstration of ectopic erythropoiesis in hepatic cytolysis].
1983 · J M Dueymes, R Despax, et al. · PubMed · 1
[Acute myelomonocytic leukemia with hyperleukocytosis. Symptomatic treatment with cytapheresis and plasma exchange].
1982 · R Despax, J M Dueymes, et al. · PubMed · 1
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Works count: 50
Citation count: 880
H-index: 9
I10-index: 9
Year
Topic
Type